Senior Director, Wound Biologics R&D

Smith+Nephew•Fort Worth, TX
•Hybrid

About The Position

The Senior Director, Wound Biologics R&D leads integrated research and development activities for one or more clinical-stage wound biologics products. The role coordinates R&D, Clinical, Medical, Regulatory Affairs, CMC/Technical Operations, Quality, Nonclinical, Biostatistics, Data Management, Manufacturing, Finance, Legal and Commercial contributors to advance programs from IND-enabling work and IND maintenance through Phase 1, Phase 2, Phase 3, marketing-application readiness and lifecycle planning. The position provides program-level leadership, governance and decision discipline while respecting the authority of Medical Monitoring, Regulatory, Quality and functional CMC owners. The leader owns the cross-functional development roadmap, critical path, stage gates, budget, resource plan, risk register, decision log and executive governance cadence. They integrate scientific, clinical, manufacturing and regulatory information into evidence-based recommendations about investment, indication sequencing, dose and regimen, manufacturing readiness, pivotal development and registration pathways. The role also leads internal experts and external partners while ensuring the company retains ownership of decisions, data and know-how. The position includes oversight of clinical development strategy and execution; IND and global regulatory planning; drug-substance and drug-product CMC strategy; manufacturing and clinical supply; quality and compliance; portfolio finance and executive governance; and organizational capability building. It requires direct practical experience across R&D and clinical development, with working leadership experience integrating CMC and Regulatory Affairs. The successful candidate will build a high-performing matrix team, communicate risks and trade-offs clearly, and keep patient safety, product quality, scientific rigor and regulatory integrity central to development decisions.

Requirements

  • Advanced degree in a life-science, pharmaceutical, biochemical engineering, medical or related discipline; a PhD, PharmD, MD or equivalent advanced scientific degree is preferred.
  • 15+ years of progressive experience in pharmaceutical, biotechnology or biologics product development within regulated environments, including significant cross-functional leadership responsibility.
  • Direct experience shepherding at least one drug or biologic program through IND and multiple clinical stages, including meaningful leadership exposure to Phase 1, Phase 2 and Phase 3 development.
  • Demonstrated depth across R&D and working leadership experience integrating CMC and Regulatory Affairs, rather than operating solely within one function.
  • Experience leading cross-functional teams spanning Clinical, Medical, Regulatory, CMC/Technical Operations, Quality, Nonclinical, Biostatistics and external development partners.
  • Working knowledge of IND development and maintenance, health-authority interactions, GCP, GMP, GLP, biologics CMC, technology transfer, comparability, CDMO governance and clinical supply.
  • Demonstrated ownership of integrated timelines, budgets, risks, governance and executive decision support.
  • Experience operating in a global matrix and influencing senior functional leaders without relying solely on line authority.
  • Excellent written and verbal communication, with the ability to make complex scientific, clinical, manufacturing and regulatory issues clear to executives and technical teams.
  • Ability to develop an approved integrated development plan spanning IND, Phase 1, Phase 2, Phase 3 and registration-readiness milestones with owners, dependencies and decision criteria.
  • Ability to deliver evidence-based development gates and health-authority interactions on time, with commitments and follow-up actions actively managed.
  • Ability to support a clinically and statistically credible study sequence with documented dose, indication, endpoint and pivotal-development rationale.
  • Ability to develop an executable CMC and clinical-supply plan with stage-appropriate specifications, stability, comparability, technology-transfer and validation pathways.
  • Ability to manage an accurate budget, forecast, resource plan and scenario-based funding requirements.
  • Ability to support timely executive decisions with concise, fact-based recommendations and transparent risk assessment.
  • Ability to reduce consultant and critical-person dependency through documented knowledge transfer and clear internal ownership.
  • Ability to ensure timely closure of material risks, actions, regulatory commitments and governance decisions.
  • Working understanding of relevant FDA requirements and ICH expectations for drug and biologic development, in partnership with accountable Regulatory and Quality leaders.

Nice To Haves

  • Experience in wound biologics, topical biologics, regenerative medicine, tissue repair, burns, dermatology, enzymes, proteins or locally acting therapies.
  • Experience with microbial fermentation, protein or enzyme drug substance, topical drug product, combination-product interfaces or advanced wound-care delivery systems.
  • Leadership of a pivotal program and contribution to a biologics license application, new drug application or equivalent global marketing application.
  • Experience with CMC technology transfer, process characterization, analytical-method lifecycle, comparability, process validation, audits and inspection readiness.
  • Experience with external-manufacturing and CDMO partnerships, including technical agreements, quality agreements, supply continuity and performance governance.
  • Experience transitioning a virtual, consultant-heavy or externally developed program into a durable corporate operating model.
  • Commercial, market-access or portfolio exposure sufficient to connect development choices to value creation and lifecycle strategy.

Responsibilities

  • Lead integrated development strategy and execution for wound biologics from IND-enabling activities and IND maintenance through Phase 1, Phase 2, Phase 3, marketing-application readiness and lifecycle planning.
  • Own the cross-functional development roadmap, critical path, stage gates, budget, resource plan, risk register, decision log and executive governance cadence.
  • Partner with PMO to integrate internal functions and external inputs into one baselined development plan.
  • Lead internal experts and external partners, including CROs, CDMOs, laboratories, consultants, investigators and scientific advisors, while retaining company ownership of decisions, data and know-how.
  • Develop evidence-based recommendations on investment, indication sequencing, dose and regimen strategy, manufacturing readiness, pivotal development and registration pathways.
  • Escalate material patient-safety, product-quality, compliance, clinical, regulatory, supply, funding and schedule risks with options and recommended actions.
  • Define and maintain the integrated development plan, target product profile, milestone baseline, critical path, decision criteria and risk-adjusted scenarios.
  • Translate scientific, clinical, CMC and regulatory information into clear trade-offs and executive governance recommendations; make assumptions and evidence gaps explicit and assign ownership.
  • Align indication strategy and development priorities with unmet wound-care needs, intended claims, competitive differentiation, reimbursement considerations and portfolio value.
  • Build a high-performing matrix team with clear role charters, decision rights, interfaces, escalation paths and closure criteria.
  • Partner with Clinical and Medical leadership on protocol strategy, dose and regimen selection, endpoints, study populations, safety surveillance and benefit-risk assessment across Phase 1, Phase 2 and Phase 3.
  • Use Phase 1 and Phase 2 findings to inform development-entry criteria, dose selection, indication and regimen confirmation, endpoint selection, statistical assumptions, pivotal-study design and Phase 3 investment recommendations.
  • Ensure Phase 3 planning integrates clinical operations, biostatistics, data management, medical monitoring, clinical supply, quality, regulatory commitments and inspection readiness.
  • Maintain program-level oversight of enrollment, data quality, safety signals, protocol deviations, product availability, vendor performance and decision timelines without superseding medical or clinical authority.
  • Ensure clinical evidence is traceable and of sufficient quality to support health-authority interactions, marketing applications and intended product claims.
  • Partner with Regulatory Affairs to define and execute IND strategy, including IND-enabling evidence, submission content, health-authority interactions, amendments, annual reports, safety reporting and regulatory commitments.
  • Anticipate regulatory questions and coordinate coherent, submission-ready evidence from clinical, nonclinical and CMC workstreams.
  • Lead integrated preparation for applicable pre-IND, end-of-Phase 1, end-of-Phase 2 and pre-submission health-authority interactions.
  • Maintain the submission roadmap and progressive registration-readiness plan, including ownership of content, source documents, data standards, gaps and remediation actions.
  • Assess the effects of clinical, manufacturing, analytical and supplier changes on the IND, comparability strategy, study execution and registration pathway.
  • Provide integrated leadership of drug-substance and drug-product CMC strategy across development stages.
  • Align process development, scale-up, technology transfer, analytical methods, specifications, stability, comparability, validation strategy, control strategy and clinical supply with the clinical and regulatory plan.
  • Ensure stage-appropriate manufacturing readiness, release testing, packaging, labeling, storage, distribution and product availability for each clinical study.
  • Lead CDMO and critical-supplier governance across technical, quality, regulatory, contractual, supply, timeline and budget dependencies.
  • Protect access to data, methods, process knowledge, reference standards and future transfer options; establish second-source or continuity strategies where justified.
  • Identify CMC changes that could affect product performance, clinical interpretation, comparability, development timing or filing readiness and drive timely cross-functional decisions.
  • Partner with Quality on stage-appropriate GxP governance, vendor qualification, quality agreements, data-integrity controls, deviation and CAPA oversight, audit readiness and inspection preparedness.
  • Ensure decisions, source documentation, analyses and development history are controlled, traceable and suitable for regulatory review.
  • Promote a culture in which participant safety, product quality, scientific rigor and regulatory integrity are non-negotiable.
  • Ensure external experts supplement capability rather than own company decisions, and require knowledge transfer, documentation and exit plans for critical roles.
  • Own the program budget, forecast, resource scenarios, commitments and contingency requirements in partnership with Finance.
  • Prepare and lead operating reviews and executive governance discussions, including decisions, trade-offs, action logs and escalation follow-up.
  • Prioritize work based on patient value, development risk, scientific strength, regulatory feasibility, supply readiness, commercial potential and return on investment.
  • Communicate program status, changes, constraints and recommendations clearly, transparently and with appropriate evidence.
  • Connect development choices to wound-care strategy, differentiation, launch readiness and lifecycle value.
  • Mentor program and functional leaders and build internal capability in biologics development, CMC, regulatory integration and cross-functional program leadership.
  • Develop a culture of ownership, constructive challenge, disciplined speed, timely escalation and measurable delivery.
  • Recommend the appropriate mix of permanent employees, shared functions and targeted external expertise.
  • Build productive relationships with clinical investigators, wound-care experts, academic institutions, development partners and external scientific advisors.

Benefits

  • 401k matching program and 401k Plus Program
  • Discounted stock options
  • Tuition reimbursement
  • Flexible personal/vacation time off
  • Paid holidays and flex holidays
  • Paid community service day
  • Medical, dental and vision coverage
  • Health Savings Account with employer contribution of $500+ annually
  • Employee Assistance Program
  • Parental leave
  • Fertility and adoption assistance program
  • Hybrid work model for most professional roles
  • Hands-on, team-customized training and mentorship
  • Discounts on fitness clubs, travel and more
© 2026 Teal Labs, Inc
Privacy PolicyTerms of Service